CD8A and cancer: Designed to activate tumour‐specific CD8+ CTL immune responses, cancer vaccines have demonstrated benefit in prostate cancer, melanoma and other cancer types (Butterfield, 2015), and several strategies have been developed for CRC (Xiang et al., 2013).